Do you know labu or those blind box figurines that instantly sell out once they hit the shelf. In fact, this craze for scarcitydriven hype, something that is rare, has a story and make people chase after it is not new at all. Over a thousand years ago, the Chinese had their own version of a limited edition trendy item.It was miso porcelain or called secret color porcelain. So today my talk is about how we can use the inspiration of blind box culture to think about ways of bringing miso porcelain this ancien ...

AI Evaluation Challenges - Current AI evaluations face problems [1] - Limitations exist in both AI and human-centric metrics for evaluating generative media [1] - Evaluating aesthetics and image/generative media is the hardest kind of AI evaluation [1] KREA.ai's Perspective - KREA.ai focuses on perceptual evaluations [1] - Krea's role involves rethinking evaluation and shaping the future of AI [1] - Krea issues a call to action regarding AI evaluation [1] Key Discussion Points - The discussion covers the historical context and compression in relation to AI evaluation [1] - The session emphasizes the importance of evaluating our evaluations [1]

IRVINE, Calif., Aug. 6, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announces the return of JUVÉDERM® Day, Wednesday, August 20. This year's holiday marks the third annual celebration of aesthetics excellence with exciting offers exclusively for Allē Members. Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes "The JUVÉD ...

Summary of AbbVie Conference Call Company Overview - **Company**: AbbVie - **Key Executives Present**: Rob Michael (CEO), Jeff Stewart (Chief Commercial Officer), Rupal Thakkar (Chief Scientific Officer), Scott Rents (CFO) [1] Financial Performance - **Sales Growth**: AbbVie reported a 22% sales growth from its ex-Humira platform, with combined sales from SkyRizzy and Renvoke expected to exceed $25 billion this year [2] - **Revenue Guidance**: Full-year revenue guidance raised to $60.5 billion, an increase of $800 million, with adjusted EPS guidance raised by $0.21 to a range of $11.88 to $12.08 [2][14] - **Quarterly Results**: Total net revenues for the quarter were $15.4 billion, reflecting a 6.5% operational growth [13] Product Performance Immunology - **SkyRizzy**: Global sales reached $4.4 billion, up 61.8% operationally, with strong market leadership in psoriasis and IBD [3][4] - **Rinvoc**: Global sales of $2 billion, up 41.2%, with strong uptake in IBD [4][5] - **Humira**: Global sales of $1.1 billion, down 58.2% due to biosimilar competition [5] Neuroscience - **Total Revenues**: Approximately $2.7 billion, up 24% operationally [7] - **Key Products**: - Raylar: Global sales of $900 million, up 16.3% - Botox Therapeutic: Global revenues of $928 million, up 14.2% - QLIPTA: Global sales of $338 million, up 47.2% [7] Oncology - **Total Revenues**: Nearly $1.7 billion, with global sales of Imbruvica at $2.9 billion, reflecting higher persistency rates for existing patients [5][14] Aesthetics - **Total Revenues**: Nearly $1.3 billion, down 8% operationally, impacted by economic challenges [6] - **Botox Cosmetic**: Global revenues of $692 million, with growth rates down [6] Research and Development Highlights - **Pipeline Progress**: Notable approvals include Emerilis for lung cancer and RINVOC for GCA [2][8] - **Innovative Acquisitions**: Acquisition of Capstan Therapeutics for CAR T platform and Gubra for obesity treatment [3][9] - **Alopecia Areata Results**: RINVOC showed significant hair regrowth results, with 54% of patients achieving over 80% scalp coverage [8][9] Strategic Outlook - **Long-term Growth**: AbbVie is well-positioned for growth with a diversified portfolio and plans for further investments in R&D and external innovation [20][21] - **Market Dynamics**: The company is navigating competitive pressures, particularly in the IL-23 class and aesthetics market, while maintaining strong performance in its core therapeutic areas [32] Additional Insights - **Biosimilar Impact**: The transition from Humira to newer products like SkyRizzy and Rinvoc is ongoing, with some patients opting for more efficacious drugs rather than biosimilars [16][17] - **Economic Conditions**: The aesthetics market is facing challenges due to lower consumer sentiment, but AbbVie remains optimistic about long-term growth potential [6][30] Conclusion - AbbVie demonstrated strong financial performance and growth across multiple therapeutic areas, with a robust pipeline and strategic acquisitions supporting its long-term outlook. The company is actively addressing competitive dynamics and economic challenges while positioning itself for future success.

RT UnpluggedFremont (@UPTeslaFremont)Aesthetics meets functionality 🤝 ...

Workplace Design Impact - Poor workplace design can reduce productivity by as much as 20% [1] - Physical work environments actively shape how people work, think, connect, and succeed [3][4] - Aesthetics, spatial configuration, and ambient factors are key dimensions of physical work environments [5][6] Aesthetics - Aesthetics communicate a company's vision, aspirations, and identity [11][12] - Personalizing workspace aesthetics can increase employee engagement and loyalty [13][14] - Strategic use of color and texture can enhance interaction and focus [15] Spatial Configuration - Spatial configuration affects movement, interaction, and collaboration within a space [22] - Spatial layouts influence perceptions of status, fairness, and equity [25] - Strategic use of shared spaces can foster informal meetings and idea generation [26] Ambient Factors - Poor ambient conditions can erode cognitive performance by as much as 50% [29] - Bringing nature indoors, adjusting lighting, and prioritizing good air quality can improve the ambient environment [30] - Optimizing ambient factors boosts focus and decision-making [29]

Workplace Design Impact - Poor workspace design can reduce productivity by as much as 20% [1] - Physical work environments actively shape how we work, think, connect, and succeed [3] - Ambient factors can erode cognitive performance by as much as 50% [30] Three Key Dimensions of Physical Work Environments - Aesthetics: Visual sensory cues defining the work environment's aura, influencing impressions and loyalty [5][11][14] - Spatial Configuration: Layout of spaces affecting movement, interaction, and collaboration, impacting perceptions of status and fairness [6][23][26] - Ambient Factors: Unseen atmospheric characteristics like temperature, lighting, air quality, and noise levels, shaping how we feel and think [6][29] Strategies for Optimizing Workspace - Define your identity and personalize your space to increase a sense of belonging [15] - Use color and texture strategically to promote interaction and focus [15][16] - Sit near people you work with and use shared spaces for informal meetings and idea generation [27] - Prioritize good air quality and adjust lighting to match natural rhythms [31][32]

Core Insights - AbbVie reported strong first-quarter results for 2025, exceeding expectations and indicating a solid start to the year, with a focus on pipeline advancements and strategic investments [2][3] Financial Performance - First-quarter diluted EPS was $0.72 on a GAAP basis, a decrease of 6.5%, while adjusted diluted EPS was $2.46, an increase of 6.5% [3][19] - Net revenues for the first quarter reached $13.343 billion, an increase of 8.4% on a reported basis and 9.8% on an operational basis [3][4] - The immunology portfolio generated global net revenues of $6.264 billion, up 16.6% on a reported basis and 18.1% operationally [3][4] - Skyrizi net revenues were $3.425 billion, reflecting a 70.5% increase on a reported basis, while Rinvoq net revenues were $1.718 billion, up 57.2% [4][19] - Humira net revenues decreased by 50.6% to $1.121 billion [4][19] - Neuroscience portfolio revenues were $2.282 billion, an increase of 16.1% [4][19] - Oncology portfolio revenues reached $1.633 billion, up 5.8% [4][19] - Aesthetics portfolio revenues were $1.102 billion, a decrease of 11.7% [4][19] Guidance and Outlook - AbbVie raised its 2025 adjusted diluted EPS guidance from $11.99 - $12.19 to $12.09 - $12.29, accounting for an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense [3][9] Recent Developments - The European Commission granted marketing authorization to Rinvoq for treating giant cell arteritis in adults, marking the eighth approved indication for the drug in the EU [7] - AbbVie announced a collaboration with Xilio Therapeutics to develop novel immunotherapies for cancer [7] - A Biologics License Application was submitted to the FDA for trenibotulinumtoxinE for treating moderate to severe glabellar lines, which could be the first neurotoxin of its kind available [7][8]